Navigation Links
Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
Date:2/24/2011

REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that David Anton, Ph.D. has been promoted to Chief Technology Officer and Senior Vice President, Process Development and Manufacturing, a new position. He will continue to report to Alan Shaw, Ph.D., President and Chief Executive Officer.

Dr. Anton joined Codexis in 2008 after a 25-year career with DuPont. He served as Vice President, Research and Development for Codexis Bioindustrials from 2008-09, and Senior Vice President, Research and Development from 2009-11.  

"Under Dave Anton's leadership, Codexis R&D has grown to an organization that today is developing commercial products and processes in four global markets – biofuels, pharmaceuticals, carbon capture and biobased chemicals," Dr. Shaw said.  "His nearly three decades of experience in technology development and commercialization – including commercial scale-up and manufacturing -  will be important as we continue our transition to a product company."  

Dr. Anton joined DuPont in 1983, and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He was a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee from 2006 to 2008.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the potential expansion of our business.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Robert Lawson, robert.lawson@codexis.com, 650-421-8137


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis to Present at the Jefferies and Pacific Crest Conferences
2. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
3. Codexis to Announce Fourth Quarter 2010 Financial Results on February 3, 2011
4. Codexis to Present at Piper Conference
5. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
6. Codexis Expands Codex® Panel Product Family at CPhI
7. Codexis to Present at the Pacific Crest Technology Leadership Forum
8. Codexis Names Peter Strumph SVP, Commercial Operations
9. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
10. Codexis, Inc. Announces Pricing of Initial Public Offering
11. Codexis Expands Pharmaceutical Manufacturing Partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):